Your Messages Inbox
Your Article Summary
See Latest ArticlesNycomed and Forest Laboratories to Collaborate on Daxas (roflumilast) for COPD
Forest Laboratories, 08/11/09
Nycomed and Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. , announced that they have entered into a definitive collaboration and distribution agreement for Daxas in the United States. Daxas is a proprietary selective phosphodiesterase 4 enzyme inhibitor that has been developed by Nycomed for the treatment of COPD and for which Nycomed submitted an NDA with the FDA in July.
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09
Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Gilead, 11/25/09
Harris Corp. Buys VA Contractor
HealthDataManagement, 11/23/09
Article Search
Sponsor